医薬品開発とは異なり、美容医療は1年程度でビジネス化が可能であり、将来的には数十億円規模の売上を目指し活動を推進する計画としている。NANO MRNA <4571> announced on the 13th that it has signed a basic agreement with Dr. Yoshio Ikeda of Tokyo Dermatology and Plastic Surgery regarding collaboration on new aesthetic medicine using mRNA for anti-aging therapy.
This collaboration will be promoted through a subsidiary planned to be established in January 2025, "Nano Rejuvenation Inc.", which will clearly separate it from the Pharmaceutical Business.
Currently, several aesthetic medical treatments, such as collagen injections, are being performed for skin rejuvenation. Among these, injecting mRNA derived from human collagen is expected to enhance the skin's regenerative power as it efficiently produces proteins with the natural structure of human beings in the skin, making it an innovative anti-aging therapy. By combining Dr. Ikeda's aging cell removal technology with the regenerative capacity of mRNA-derived proteins, the goal is to develop safe and groundbreaking aesthetic medicine alongside Dr. Ikeda, aiming to 'rejuvenate the skin of a 70-year-old to that of a 20-year-old.'
Unlike pharmaceutical development, aesthetic medicine can be commercialized in about a year, and activities are planned to promote sales targeting several billion yen in the future.
